权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

OSU as a Network Lead Academic Participating Site for the NCI NCTN

OSU 作为 NCI NCTN 网络主导学术参与网站

基本信息

批准号：
10581614
负责人：
DAVID P. CARBONE
金额：
$ 96.83万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-03-28 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10581614
关键词：
Address Adult Advisory Committees Affect Ally Area Award Basic Science Biochemistry Biological Markers Biomedical Research Biometry Biotechnology CEBPA gene Cancer Biology Cancer Center Cancer Hospital Cancer Patient Center for Translational Science Activities Clinic Clinical Clinical Data Clinical Investigator Clinical Research Clinical Sciences Clinical Trials Clinical Trials Network Comprehensive Cancer Center Contracts Credentialing Data Databases Decitabine Dedications Discipline Disease Education Educational process of instructing Educational workshop Eligibility Determination Enrollment Environment Epidemiologist FLT3 gene Faculty Fostering Funding Generations Goals Grant Growth Gynecologic Oncology Health Personnel Hematologic Neoplasms Hematology Hematopoietic Neoplasms Image Immunologics Immunology Infrastructure Inpatients Investigational Therapies Knowledge Laboratory Scientists Lead Leadership Learning Malignant Neoplasms Medical Medical Oncology Mentored Clinical Scientist Development Program Mentors Modeling Molecular Genetics NCI Center for Cancer Research National Clinical Trials Network Nurses Oblimersen Ohio Operative Surgical Procedures Outcome Outpatients Pathologist Patient-Focused Outcomes Patients Peer Review Pentostatin Performance Pharmacists Pharmacology Phase Physicians Postdoctoral Fellow Protocols documentation Psychiatrist Quality of life Radiation Oncologist Radiation Oncology Radiation therapy Reproduction spores Research Research Activity Research Design Research Institute Research Personnel Resources Science Scientist Site Solid Neoplasm Structure Support Groups Surgical Oncologist Surgical Oncology Symptoms Therapeutic Therapeutic Agents Tissues Toxic effect Training Translating Translational trial Tumor Biology Universities cancer clinical trial cancer prevention cancer therapy career career development college confirmatory trial data submission design doctoral student drug development efficacy evaluation experience high standard improved improved outcome innovation investigator-initiated trial lenalidomide leukemia meetings minority patient multidisciplinary multimodality next generation novel novel therapeutics operation participant enrollment patient population pre-clinical pre-doctoral preclinical study programs recruit research study risk stratification rituximab success targeted treatment translational scientist treatment trial tumor heterogeneity volunteer

项目摘要

PROJECT SUMMARY The goal of this application is to provide the infrastructure to support The Ohio State University's (OSU) participation in the scientific and clinical research activities of the NCI's NCTN Program as a Network Lead Academic Participating Site (OSU-LAPS). Faculty from OSU are integrated into the scientific and administrative activities, participate in meetings, manage multiple core labs, design studies and enroll patients in all existing adult NCTN network groups using OSU Comprehensive Cancer Center (OSUCCC) resources to leverage group resources. OSUCCC investigators develop and lead studies designed to enroll patients on multi-disciplinary treatment trials as well as develop and perform correlative science related research studies, bringing special expertise in hematologic malignancies and solid tumors. Our medical, hematologic, surgical and radiation oncologists, transplanters, psychiatrists, pathologists, cytogeneticists, translational and basic laboratory scientists, statisticians, epidemiologists, nurses, pharmacists, and clinical research coordinators help to frame the clinical and basic science questions whose answers contribute to improved patient outcomes and to understanding tumor biology. OSU-LAPS will offer innovative NCI trials to the OSU patient population, support scientific discoveries about tumor biology, find better treatments, and augment the quality of life for patients thus improving outcomes across the spectrum of cancers affecting adults. This comprehensive program aims to: 1) investigate new therapeutic agents, and their toxicities in Phase I to III NCI clinical trials; 2) evaluate the efficacy and toxicity of novel combinations based on preclinical data to exploit synergistic combinations more effectively; 3) develop multi-modal approaches using surgical, immunological, and radiotherapeutic therapies in optimal combinations; 4) integrate experts in molecular genetics, biochemistry, pharmacology, immunology, and biostatistics in the design and execution of therapeutic protocols; 5) improve cancer outcomes through discovery and education of pre and post-doctoral students, nurses, allied medical personnel and physicians, 6) understand and exploit tumor heterogeneity to fully exploit the value of targeted therapies, 7) improve the management of cancer related symptoms, 8) form the next generation of clinical investigators by offering them formal teaching and mentoring within the NCTN, and 9) enroll volunteering patients on trials.

项目总结